Author Archives: admin


Stem Cell Clinic > Articles by: admin

QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board – Business Wire

By Stell Cell Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the appointment of Angela Genge, MD, FRCP(C), eMBA to the position of Chief Medical Officer (CMO). Dr. Genge is the Executive Director of the Montreal Neurological Institutes Clinical Research Unit and the Director of Montreal Neurological Hospitals ALS Global Center of Excellence.

The company also announced the formation of its Clinical Advisory Board, which will work closely with Dr. Genge on QurAlis clinical research and development programs in ALS and frontotemporal dementia (FTD) as the company prepares to move its pipeline to the clinical stage.

As QurAlis grows and advances quickly toward the clinic, we are proud to welcome to the team Dr. Genge, a world-renowned expert in ALS clinical drug development, and announce the highly esteemed group of ALS experts who will be forming our Clinical Advisory Board, said Kasper Roet, PhD, Chief Executive Officer of QurAlis. Dr. Genge has been treating patients and studying and developing therapeutics and clinical trials for ALS and other rare neurologic diseases for more than 25 years, diligently serving these vulnerable patient populations. Along with our newly formed Clinical Advisory Board, having a CMO with this extensive expertise, understanding and experience is invaluable to our success. Dr. Genge and our Board members are tremendous assets for our team who will undoubtedly help us advance on the best path toward the clinic, and we look forward to working with them to conquer ALS.

Previously, Dr. Genge directed other clinics at the Montreal Neurological Hospital including the Neuromuscular Disease Clinic and the Neuropathic Pain Clinic. In 2014, she was a Distinguished Clinical Investigator in Novartis Global Neuroscience Clinical Development Unit, and she has served as an independent consultant for dozens of companies developing and launching neurological therapeutics. Dr. Genge has served in professorial positions at McGill University since 1994.

At this pivotal period in its journey, QurAlis is equipped with a strong, committed leadership team and promising precision medicine preclinical assets, and I look forward to joining the company as CMO, said Dr. Genge. This is an exciting opportunity to further strengthen my work in ALS and other neurological diseases, and I intend to continue innovating and expanding possibilities for the treatment of rare neurological diseases alongside the dedicated QurAlis team.

QurAlis new Clinical Advisory Board Members are:

Dr. Al-Chalabi is a Professor of Neurology and Complex Disease Genetics at the Maurice Wohl Clinical Neuroscience Institute, Head of the Department of Basic and Clinical Neuroscience, and Director of the Kings Motor Neuron Disease Care and Research Centre. Dr. Al-Chalabi trained in medicine in Leicester and London, and subsequently became a consultant neurologist at Kings College Hospital.

Dr. Andrews is an Associate Professor of Neurology in the Division of Neuromuscular Medicine at Columbia University, and serves as the Universitys Director of Neuromuscular Clinical Trials. She currently oversees neuromuscular clinical trials and cares for patients with neuromuscular disease, primarily with ALS. Dr. Andrews is the elected co-chair of the Northeastern ALS (NEALS) Consortium and is also elected to the National Board of Trustees of the ALS Association.

Dr. Cudkowicz is the Julianne Dorn Professor of Neurology at Harvard Medical School and Chief of Neurology and Director of the Sean M. Healey & AMG Center for ALS at Mass General Hospital. As co-founder and former co-chair of the Northeast ALS Consortium, she accelerated the development of ALS treatments for people with ALS, leading pioneering trials using antisense oligonucleotides, new therapeutic treatments and adaptive trial designs. Through the Healey Center at Mass General, she is leading the first platform trial for people with ALS.

Dr. Shaw serves as Director of the Sheffield Institute for Translational Neuroscience, the NIHR Biomedical Research Centre Translational Neuroscience for Chronic Neurological Disorders, and the Sheffield Care and Research Centre for Motor Neuron Disorders. She also serves as Consultant Neurologist at the Sheffield Teaching Hospitals NHS Foundation Trust. Since 1991, she has led a major multidisciplinary program of research investigating genetic, molecular and neurochemical factors underlying neurodegenerative disorders of the human motor system.

Dr. Van Damme is a Professor of Neurology and director of the Neuromuscular Reference Center at the University Hospital Leuven in Belgium. He directs a multidisciplinary team for ALS care and clinical research that is actively involved in ALS clinical trials, but is also working on the genetics of ALS, biomarkers of ALS, and disease mechanisms using different disease models, including patient-derived induced pluripotent stem cells.

Dr. van den Berg is a professor of neurology who holds a chair in experimental neurology of motor neuron diseases at the University Medical Center Utrecht in the Netherlands. He also is director of the centers Laboratory for Neuromuscular Disease, director of the Netherlands ALS Center, chairman of the Neuromuscular Centre the Netherlands, and chairman of the European Network to Cure ALS (ENCALS), a network of the European ALS Centres.

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the ALS community by developing breakthrough precision medicines for this devastating disease. Our stem cell technologies generate proprietary human neuronal models that enable us to more effectively discover and develop innovative therapies for genetically validated targets. We are advancing three antisense and small molecule programs addressing sub-forms of the disease that account for the majority of patients. Together with a world-class network of thought leaders, drug developers and patient advocates, our team is rising to the challenge of conquering ALS. http://www.quralis.com

See more here:
QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board - Business Wire

Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development – SelectScience

By Stem Cell Medical Center

Gene and cell therapy expert Dr. Gerhard Bauer explores the powerful therapies that use a patient's own immune cells to treat cancer

In this article, we hear from Dr. Gerhard Bauer, Professor of Hematology-Oncology at the UC Davis Medical Center within the School of Medicine and Director and Designer of the UC Davis Good Manufacturing Practice Facility. Following his earlier research on stem cell gene therapy for HIV and severe combined immune deficiency (SCID), Bauer discusses his current work overseeing the development of life-saving CAR-T cells, highlights how new self-sterilizing instruments have been critical to his teams production of safe gene therapy products for patients, and shares his hopes for the future.

Tell us more about the Good Manufacturing Practice Lab at the UC Davis Institute, and your journey to becoming director

GB: In my early years, I helped operate a laboratory in Vienna testing laboratory blood products for HIV. Until finally, I thought, if I really want to do something about HIV and want to find a treatment or cure for it, then I need to do more than just testing test kits. I was subsequently hired by the University of Maryland at Baltimore to run the HIV laboratory. Whilst there I was able to find a predictor for HIV transmission, from mother to child, which at that time was a cell-based assay designed to predict the transmission rate. From this, we were able to demonstrate that higher viral load leads to more transmission.

I was then asked to move over to the Johns Hopkins University, where I started on the development of stem cell gene therapy for HIV. And then on to Dr. Donald Kohn's laboratory at Children's Hospital Los Angeles, where I was fortunate enough to be able to work on developing all the clinical-grade procedures to transport genes into hematopoietic stem and progenitor cells. This research led to the development of a completely new treatment for ADA-deficient SCID, severe combined immune deficiency.

After the success of the clinical-grade procedures, I was asked to go to Washington University in St. Louis, to build them a completely new Good Manufacturing Practice facility for cell and gene therapy. This was because I had built a GMP facility among the first academic GMP facilities at Children's Hospital Los Angeles. A few years later I moved to California to help build another GMP facility at University of California, Davis, where I am still conducting my research.

The UC Davis Medical Center is a manufacturing facility for cell and gene therapy products that are being used in clinical trials to help treat patients with currently incurable diseases. In this aspect, I overlook all the manufacturing efforts for novel clinical trials. Since 2010, we have been operating very successfully and have a whole pallet of applications, cell and gene therapy, and other applications that we manufacture here.

What are the main goals for your projects using homegrown CAR-T cell therapy approaches?

GB: A very interesting project that we have been tackling is CAR-T cells. Everybody talks about CAR-T cells these days because they have turned from an experimental project into commercialized applications. CAR-T cells are chimeric antigen receptor T cells. They are gene-modified immune cells from the patient. You can take a patient's immune cells, specifically T cells, out in a blood collection procedure, put them into a laboratory, and then insert genes that will produce a completely novel receptor on the cell surface that can recognize cancer cells. Chemotherapy and radiotherapy only kill the fast-growing tumor cells but often a patient will have a relapse. The relapse comes from cells that have survived the chemotherapy or radiation.

The immune system, if properly equipped, allows for the surveillance of all the cancer cells that may still be there even after chemotherapy. With CAR-T cells, we have developed such a weapon that allows the patient's own immune system to recognize the cancer and eliminate it. This can also be sustained elimination because the T cells develop memory T cells that will be reactivated when the cancer comes back.

In my career here at UC Davis, I have been involved in several CAR-T cell projects initiated by biotech companies. Also, another one initiated by UC Davis in collaboration with University of California, San Francisco. And we are manufacturing such CAR-T cells in the laboratory currently and we are initiating investigational new drug applications, INDs, with the FDA to apply these homegrown CAR-T cells as we call them to patients in San Francisco and also here at UC Davis.

What role do incubators play in cell and gene therapy development?

GB: Within a Good Manufacturing Practice laboratory, we need equipment that can be calibrated and that can maintain the operational status in a very precise way, from beginning to end of the process. Also, we must be able to clean these pieces of equipment appropriately. This means we maintain a very clean environment so as not to cross-contaminate or bring any other infections in. It is very important that we get laboratory equipment that can handle all of this.

I have had a good experience with the incubators that we have had over the years in our laboratories. Some had lasted for over 10 years until we replaced them with newer incubators with a unique feature. That feature is a self-sterilizing incubator, which has helped us tremendously in our efforts. We need to keep the time that we work on maintenance of the equipment low because our technicians are needed for making the products. We do not have to do an autoclaving step on the shelves and everything that is in there. We can leave everything in, and it sterilizes itself. It has saved us so much time and effort and our technicians are grateful for that.

Without these incubators, I do not think we would be able to efficiently produce as many products as we do currently. We also must make sure that we produce a safe and efficacious patient product if we do not have reliable incubators, we cannot make reliable products.

What is your vision for the future of gene therapy?

GB: Up to now we have been able to demonstrate that gene therapy is very safe. We have seen so many patients cured with ADA-deficient SCID safely. In CAR-T cell therapy, which is also a gene therapy, we have saved the lives of so many patients safely.

In the future, we need to expand these already working methods. We must make CAR-T cell therapy available for the many people that need it. Often scaling up is not possible because it is an autologous therapy. I would say scale out, not scale up. Scaling out means that you have many different laboratories where you can make these products and each product is being made in an efficient way. We are going to have to develop methods to efficiently manufacture these products side by side. This will be possible with automation.

Hopefully, in a few years down the road, we will be able to provide those who need it with cell and gene therapy. The second thing is that it is likely that genetic diseases will be curable with gene therapy, more of these cures are being worked on currently. Not only is cell therapy involved in that, but gene therapy vectors can also be administered directly into the patient to look for the cells they need to cure, and then illicit the cure directly without having to transplant cells. So, the future is very interesting, and having seen it from the very beginning to where we are now is something that I really enjoy.

More on the impact of PHCbi technology:

Find out more about Dr. Gerhard Bauers research here>>

Do you use PHCbi products in your lab? Write a review today for your chance to win a $400 Amazon gift card>>

Read the original:
Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development - SelectScience

Richters Transformation: When a Slow-Growing Cancer Turns Aggressive – SurvivorNet

By Stem Cell Medical Center

Dr. Nicole Lamanna Columbia University Medical Center

Chronic lymphocytic leukemia (CLL) is a slow-growing type of cancer. It grows so slowly, in fact, that you can live for many years with your cancer, without having any symptoms or needing treatment. Sometimes, though, CLL can suddenly turn into a more serious condition, a change called Richters transformation.

Richters transformation is a condition in a small subset of CLL patients about 10 to 15% of patients where their disease can transform to a more aggressive lymphoma, Dr. Nicole Lamanna, associate professor of medicine at Columbia University Medical Center, tells SurvivorNet.

CLL often changes into a type of non-Hodgkin lymphoma called diffuse large B-cell lymphoma. Rarely, it turns into a form of Hodgkin lymphoma. If your cancer does change, your doctor will need to put you on a more aggressive treatment to control it.

Doctors dont know exactly why CLL suddenly takes a more serious turn. One theory is that certain people have a few aggressive cancer cells hidden behind their slow-growing ones. Eventually, those cells multiply to the point where they change into a new kind of lymphoma and take over.

How do you know that your cancer has transformed? Theres a big change in their disease, says Dr. Lamanna.

Look for signs like these:

Another important clue is the size of your lymph nodes. They may have a lymph node thats growing out of proportion to whats going on with the rest of their body, Dr. Lamanna says.

Lymph nodes are the little bean-shaped bumps in your neck, armpit, belly, and groin area. Youve likely felt them swollen in your neck at some point when you had an infection. If you notice any unusual swelling in these areas, tell the doctor who treats your cancer about it.

Richters transformation leads to a totally different disease than CLL, and it requires a different kind of treatment. Unlike CLL, which is chronic and we can treat intermittently or over the years, this is something they cant live with, Dr. Lamanna tells SurvivorNet. This is a much more difficult condition to treat.

Doctors usually use the same treatment as they do for large cell lymphoma, she adds. That can be a cocktail of chemotherapy drugs such as R-CHOP the monoclonal antibody rituximab (Rituxan), plus a combination of three chemotherapy drugs and the steroid, prednisone. Or, it can include a different monoclonal antibody called obinutuzumab (Gazyva) plus other combinations of chemo drugs such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin) or ICE (ifosfamide, carboplatin, etoposide).

Because of the aggressiveness of this disease, some people will ultimately need a stem cell transplant. This treatment starts with high doses of chemotherapy to destroy the cancer cells. Thats followed by an infusion of stem cells immature blood cells either from yourself or a donor. Those cells will grow into healthy new blood cells.

Researchers are studying new combinations of drugs, such as monoclonal antibodies paired with the targeted drug ibrutinib (Imbruvica) or other targeted therapies, to see if they work better against this cancer. This is an area under a lot of investigation. Were looking for new therapies all the time, Dr. Lamanna says.

In the meantime, your situation will determine which treatment your doctor recommends for you. Try to learn as much as you can about your new type of cancer. Dont be afraid to ask questions, including why your doctor is suggesting a specific treatment, how it might help you, and what side effects it could cause. Because this is an aggressive cancer, make sure you have the support you need, whether thats from your family, your medical team, or a lymphoma support group.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Nicole Lamanna is a hematologist/oncologist at Columbia University Medical Center. Her research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia (CLL). Read More

Dr. Nicole Lamanna Columbia University Medical Center

Richters transformation is a condition in a small subset of CLL patients about 10 to 15% of patients where their disease can transform to a more aggressive lymphoma, Dr. Nicole Lamanna, associate professor of medicine at Columbia University Medical Center, tells SurvivorNet.

Doctors dont know exactly why CLL suddenly takes a more serious turn. One theory is that certain people have a few aggressive cancer cells hidden behind their slow-growing ones. Eventually, those cells multiply to the point where they change into a new kind of lymphoma and take over.

How do you know that your cancer has transformed? Theres a big change in their disease, says Dr. Lamanna.

Look for signs like these:

Another important clue is the size of your lymph nodes. They may have a lymph node thats growing out of proportion to whats going on with the rest of their body, Dr. Lamanna says.

Lymph nodes are the little bean-shaped bumps in your neck, armpit, belly, and groin area. Youve likely felt them swollen in your neck at some point when you had an infection. If you notice any unusual swelling in these areas, tell the doctor who treats your cancer about it.

Richters transformation leads to a totally different disease than CLL, and it requires a different kind of treatment. Unlike CLL, which is chronic and we can treat intermittently or over the years, this is something they cant live with, Dr. Lamanna tells SurvivorNet. This is a much more difficult condition to treat.

Doctors usually use the same treatment as they do for large cell lymphoma, she adds. That can be a cocktail of chemotherapy drugs such as R-CHOP the monoclonal antibody rituximab (Rituxan), plus a combination of three chemotherapy drugs and the steroid, prednisone. Or, it can include a different monoclonal antibody called obinutuzumab (Gazyva) plus other combinations of chemo drugs such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin) or ICE (ifosfamide, carboplatin, etoposide).

Because of the aggressiveness of this disease, some people will ultimately need a stem cell transplant. This treatment starts with high doses of chemotherapy to destroy the cancer cells. Thats followed by an infusion of stem cells immature blood cells either from yourself or a donor. Those cells will grow into healthy new blood cells.

Researchers are studying new combinations of drugs, such as monoclonal antibodies paired with the targeted drug ibrutinib (Imbruvica) or other targeted therapies, to see if they work better against this cancer. This is an area under a lot of investigation. Were looking for new therapies all the time, Dr. Lamanna says.

In the meantime, your situation will determine which treatment your doctor recommends for you. Try to learn as much as you can about your new type of cancer. Dont be afraid to ask questions, including why your doctor is suggesting a specific treatment, how it might help you, and what side effects it could cause. Because this is an aggressive cancer, make sure you have the support you need, whether thats from your family, your medical team, or a lymphoma support group.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Nicole Lamanna is a hematologist/oncologist at Columbia University Medical Center. Her research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia (CLL). Read More

Link:
Richters Transformation: When a Slow-Growing Cancer Turns Aggressive - SurvivorNet

Detroit Pistons, Make-A-Wish put a smile on the face of Commerce Township boy – The Oakland Press

By Stem Cell Medical Center

In the spring Dylan Findling seemed to be a typical 9-year-old boy who loved sports.

His parents thought he might have attention deficit hyperactivity disorder but they didnt suspect a serious disease.

When COVID hit and I was kind of staying at home to work with him at home we started to know he was having balance issues. He was having issues kind of tracking when he was reading, he would fall all the time. I thought hes getting taller so maybe hes going through an awkward stage, his mom, Elissa Findling said.

Then it got more progressive and he could no longer ride his bike which he had done since he was 5.

Due to COVID-19 lockdowns of non-essential medical appointments, he couldnt get into an eye doctor until May 29.

His dad, Michael, took him for the appointment. It was discovered he had pressure on both optic nerves and was sent to the emergency room at Detroit Medical Center. An MRI revealed the bad news.

Dylan was diagnosed that day with Adrenoleukodystrophy (ALD), a genetic brain disorder. He also has Addisons Disease. The two go hand in hand. He was in kidney failure and his parents didnt know it.

Theres a very easy test to determine whether your child might have ADHD versus this disease. Its a blood test but not a required test they ask pediatricians to do, Elissa Findling said. The sad thing is Dylans disease is so far progressed that hes not eligible for what would cure it which is a bone marrow transplant.

They didnt like the news they were told that night.

We were told to go home and enjoy our time. Were not that kind of people - that wasnt a good enough answer, Findling said.

The Commerce Township couple contacted a specialist in Minnesota and through him Dylan has been undergoing an experimental treatment to stop progression of the disease at Beaumont.

In July when Dylan started the treatments he was still able to walk, talk, run, play, like a normal 9 year old. He just had some balance issues. In a matter of weeks he went from being able to do all of that, hes wheelchair bound. He cant talk, he has a G tube. This decline that weve seen has happened very quickly for him and for us, its obviously been hard for our family, his mom said.

The hope is to stop progression of the disease and then he might be eligible for a stem cell transplant.

Theyre thinking this may stop his disease, but I dont know that well get back what we had. Hes going to always be disabled which is hard to swallow and so thats where were at, Findling said. We go to therapy four days a week. Were doing the best we can with it.

Along the way, the staff at Beaumont mentioned Dylan would be eligible for a wish from the Make-A-Wish Foundation. They came through big-time along with the Detroit Pistons.

Due to the coronavirus pandemic, Make-A-Wish cant offer trips and meeting a celebrity can only happen with a Zoom call.

The Findlings were familiar with Make-A-Wish because their older son, Evan, survived Burkitts Lymphoma. While he was going through it they were granted the wish of going on a family cruise. Hes in remission.

So now they had to come up with a wish for Dylan.

At some point hed gravitated to always wearing jerseys to school. Hed wear Pistons jersey, soccer jerseys, and hed have football jerseys. All the kids knew him for being the jersey kid. He always loved sports and jerseys for sure, his dad Michael Findling said.

So he decided he would like to design a Detroit Pistons jersey.

When all of this came crashing down in such a short period of time that was the thing that came up for the Make A Wish, he loved jerseys, he liked sports and he cant do it any longer so this was a way to marry the two together. I thought they did an amazing job of putting it together for him, Michael Findling said.

The jersey design process, with Dylans help, was done on Zoom.

Then this week the Pistons brought the show to the Findling home in Commerce Township. They had a rubber mat for a runway with dance team members modeling the jerseys Dylan designed. Even the mascot, Hooper, was present and wearing the special jersey which includes a blue ribbon honoring ALD. There were jerseys, hats, T-shirts, face masks and much more for Dylan.

Dylan had a big smile on his face all that morning.

With all the swag that hes gotten its going to keep giving to him, because we can show him new things all the time hes going to love having the socks on. It definitely got him excited, his dad said.

Elissa Findling said, I dont know if thank you covers it.

This experience will be shared by the family on social media, hoping to spread awareness about ALD.

Right before he lost the ability to talk, he was talking a lot to me - he knew his brother had been sick, it was a rare cancer. We were talking about how rare his disease is and trying to make him understand its not your fault that youre sick, you didnt do anything wrong, Elissa Findling said. He was like. You know mommy since its so rare we could try to find something to cure me. That stuck with me through this process - thinking if we could do some good from it.''

ALD generally affects boys ages 2-11 and can be diagnosed through a blood test.

The key is to catch it early, the child can get a bone marrow transplant and its basically cured. If you dont, then youre going to deal with what were dealing with and we dont want to see another family dealing with this, Elissa Findling said.

Read the original post:
Detroit Pistons, Make-A-Wish put a smile on the face of Commerce Township boy - The Oakland Press

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia – Yahoo Finance

By Stem Cell Medical Center

City of Hope will combine its world-leading expertise with NexImmune technology to explore tumor escape mechanisms and to identify unique leukemia stem cell targets for next generation immunotherapeutics

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the centers tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.

NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Companys AIM nanoparticle technology.

NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML, said Guido Marcucci, M.D., Chair and Professor with City of Hopes Department of Hematologic Malignancies Translational Science. Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.

A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.

Story continues

In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.

Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmunes AIM technology and T cell products, said Monzr Al Malki, M.D., Director of City of Hopes Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. Based on our current clinical experience with this technology, were excited to learn what more this research will tell us.

City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world, said Han Myint, M.D., NexImmune Chief Medical Officer. The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.

City of Hope is a leader in bone marrow transplantation. More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hopes BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

About NexImmune NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Companys pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.

For more information, visit http://www.neximmune.com.

Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 mikebeyer@sambrown.com

Investor Contact: Chad Rubin Solebury Trout +1-646-378-2947 crubin@soleburytrout.com

Read more:
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - Yahoo Finance

Induced Pluripotent Stem Cells Industry Market 2020 Global Trends, Key Players, Share, Growth, Analysis, Opportunities and Forecast To 2026 -…

By Induced Pluripotent Stem Cells

A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Induced Pluripotent Stem Cells Industry Market. On the basis of historic growth analysis and current scenario of Induced Pluripotent Stem Cells Industry market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that facilitate deeper understanding of multiple aspects of global Induced Pluripotent Stem Cells Industry market. This further helps users with their developmental strategy.

This report examines all the key factors influencing growth of global Induced Pluripotent Stem Cells Industry market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Induced Pluripotent Stem Cells Industry market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

For Better Understanding, Download FREE Sample Copy of Induced Pluripotent Stem Cells Industry Market Report @ https://www.crediblemarkets.com/sample-request/induced-pluripotent-stem-cells-industry-market-831622

Data presented in global Induced Pluripotent Stem Cells Industry market report allows users to realize their market entry potential and devise fruitful developmental strategies to fulfil their business goals. A report sample can be requested to view the report outline before you actually purchase it.

Key players in the global Induced Pluripotent Stem Cells market covered in Chapter 12:

Bone Therapeutics SA System Biosciences Axiogenesis Regeneus Ltd. Cellectics CellTherapies P/L Cellular Dynamics Reprocell BrainStorm Cell Therapeutics Inc. Iperian Stemgent Fate Therapeutics Viacyte Lonza Organogenesis Inc. Waisman Biomanufacturing Ocata Therapeutics Inc. Medipost Co. Ltd.

In Chapter 4 and 14.1, on the basis of types, the Induced Pluripotent Stem Cells market from 2015 to 2025 is primarily split into:

Adult Sources Fetal Sources Others

In Chapter 5 and 14.2, on the basis of applications, the Induced Pluripotent Stem Cells market from 2015 to 2025 covers:

Hematopoietic stem cell transplantation Tissue repair damage Autoimmune diseases As gene therapy vectors

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.crediblemarkets.com/enquire-request/induced-pluripotent-stem-cells-industry-market-831622

Some Points from Table of Content

COVID-19 Outbreak-Global Induced Pluripotent Stem Cells Industry Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Chapter 1 Induced Pluripotent Stem Cells Industry Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global Induced Pluripotent Stem Cells Industry Market, by Type

Chapter 5 Induced Pluripotent Stem Cells Industry Market, by Application

Chapter 6 Global Induced Pluripotent Stem Cells Industry Market Analysis by Regions

Chapter 7 North America Induced Pluripotent Stem Cells Industry Market Analysis by Countries

Chapter 8 Europe Induced Pluripotent Stem Cells Industry Market Analysis by Countries

Chapter 9 Asia Pacific Induced Pluripotent Stem Cells Industry Market Analysis by Countries

Chapter 10 Middle East and Africa Induced Pluripotent Stem Cells Industry Market Analysis by Countries

Chapter 11 South America Induced Pluripotent Stem Cells Industry Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global Induced Pluripotent Stem Cells Industry Market Forecast

Chapter 15 New Project Feasibility Analyses

Direct Purchase Induced Pluripotent Stem Cells Industry Market Research Report Now @ https://www.crediblemarkets.com/reports/purchase/induced-pluripotent-stem-cells-industry-market-831622?license_type=single_user

Points Covered in the Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Impact of Covid-19 in Induced Pluripotent Stem Cells Industry Market: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Induced Pluripotent Stem Cells Industry market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Browse the Short Summary & TOC of the Report @ https://www.crediblemarkets.com/reports/induced-pluripotent-stem-cells-industry-market-831622

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Continue reading here:
Induced Pluripotent Stem Cells Industry Market 2020 Global Trends, Key Players, Share, Growth, Analysis, Opportunities and Forecast To 2026 -...

The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 – PRnews Leader

By Induced Pluripotent Stem Cells

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors. These stem cell-derived cells are then developed using a complete culture system that is an easy-to-use system used for defined iPS-derived cell expansion. Majority of the key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/28780

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/28780

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

You Can Request for TOC[emailprotected]

https://www.persistencemarketresearch.com/toc/28780

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

Excerpt from:
The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader

In Vitro Toxicology Testing Market: Facts, Figures and Analytical Insights, 2018 to 2024 – Aerospace Journal

By Induced Pluripotent Stem Cells

This market research report identifies Laboratory Corporation of America Holdings, Charles River Laboratories, Inc, Thermo Fisher Scientific, Eurofins Scientific, Agilent Technologies, Inc., as the major vendors operating in the global in vitro toxicology testing market. This report also provides a detailed analysis of the market by toxicology end points (systemic toxicity, cytotoxicity testing, genotoxicity testing, ocular toxicity, organ toxicity, dermal toxicity, neurotoxicity, and others), industry type (pharmaceutical and biopharmaceutical, cosmetics, chemical, diagnostics, and food industry), and region (North America, Europe, Asia Pacific, and Rest of the World).

Infoholics market research report predicts that the globalin vitro toxicology testing marketwill grow at a CAGR of8.2%during the forecast period 20182024. The market for in vitro toxicology testing is driven by high opposition to animal testing, increased cost related to animal-based toxicity testing, and increasing R&D expenditure for early stage toxicity testing. Whereas, the lack of in vitro models and decreased adoption rate are limiting the growth of the in vitro toxicology testing market to an extent.

Request For Report Sample: https://www.trendsmarketresearch.com/report/sample/9863

According to the in vitro toxicology testing market analysis, Europe accounted for the largest share of the global in vitro toxicology testing market followed by North America in 2017. The reason is the upsurge in the investments by the European Commission in R&D to develop substitute methods to in vitro testing is driving the demand in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period due to increasing number of contract research organizations offering testing services, advancements in healthcare infrastructure, increasing investments in the biopharmaceutical sector, and upward economic conditions in the region.

Competitive Analysis and Key Vendors:

There is an increase in collaborations between companies on in vitro testing of compounds. For instance, in December 2016, Evotec and Celgene entered into a drug discovery collaboration for neurodegenerative diseases. According to agreement terms, Celgene will use Evotecs unique induced pluripotent stem cell (iPSC) platform that enables systematic drug screening in patient-derived disease models. In June 2017, Censo Biotechnologies Ltd. collaborated with Evotec AG to source and provide patient-derived induced pluripotent stem cells to support Evotecs drug discovery iPSC platform. In addition, the companies are also coming up with new products for in vitro testing. For instance, in January 2018, STEMCELL Technologies Inc. released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the laboratory.

Some of the In Vitro Toxicology Testing Market key vendors are:

Other prominent vendors in the global in vitro toxicology testing market are Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories, Gentronix Limited, Promega Corporation, MB Research Laboratories, Evotec AG (Cyprotex plc), Catalent, Inc., Qiagen N.V., and niche players.

Request for Report Discount @https://www.trendsmarketresearch.com/report/discount/9863

In Vitro Toxicology Testing Market by Toxicology End Points:

In 2017, the systemic toxicity accounted for the highest market share due to the availability of a wide range of sub-studies, which ensure total analysis of toxicity and safety margin of the testing compounds.

In Vitro Toxicology Testing Market by Industry type:

In 2017, the pharmaceutical and biopharmaceutical industry occupied significant market share and the cosmetics industry is expected to hold a high percentage during the forecast period. Increased support of regulatory authorities to use in vitro and in silico methods instead of animal testing to check toxicology is driving the growth of the cosmetic industry.

In Vitro Toxicology Testing Market Benefits:

The report provides detailed information about the services offered by in vitro toxicology testing in various therapeutic verticals and regions. With that, key stakeholders can find out the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Additionally, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the in vitro toxicology testing market.

Covid 19 Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/9863

Continued here:
In Vitro Toxicology Testing Market: Facts, Figures and Analytical Insights, 2018 to 2024 - Aerospace Journal

Bayer Acquires AskBio to Expand Gene Therapy Platform – PharmaLive

By Induced Pluripotent Stem Cells

Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio). Bayer is paying $2 billion upfront for AskBios AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.

AskBios Pro10 AAV manufacturing process has become something of a standard across the industry. The platform is used by multiple companies, including Pfizer, Takeda and Viralgen Vector Core SA. The company holds over 500 patents in areas such as AAV production, chimeric vectors and self-complementary DNA. AskBios technology has already seen regulatory success. It initially developed the gene therapy for spinal muscular atrophy that Illinois-based AveXis, a subsidiary of Novartis, won approval for from the U.S. Food and Drug Administration in 2019. AskBios lead research programs, which are focused on Pompe disease, Parkinsons disease and congestive heart failure are currently in early phases of clinical development.

Under terms of the deal, Bayer will own full rights to AskBios pipeline of treatments for Pompe disease, Parkinsons disease, as well as therapies for neuromuscular, central nervous system, cardiovascular and metabolic diseases. AskBio will remain an autonomous company under the Bayer umbrella and will operate on an arms-length basis, Bayer said this morning. AskBio Chief Executive Officer Sheila Mikhail noted that her company will retain its independent structure, which she said will allow them to provide accelerated development of gene therapies to treat more patients who can benefit from them.

Our innovation in capsid re-engineering and promoter design, coupled with our scaled manufacturing processes, gives us the tools to provide gene therapy solutions to more people suffering from a wider spectrum of disease that is not being adequately treated today, added Richard Jude Samulski, AskBios chief scientific officer. Samulski was the first scientist to clone AAV.

The acquisition of AskBio will bolster Bayers cell and gene therapy business and will lay the foundation for future partnerships in the area of adeno-associated virus (AAV) therapies, Bayer said. Besides multiple clinical-stage assets for indications with highly unmet needs, the acquisition includes a state-of-the-art gene therapy technology platform as well as existing gene therapy manufacturing platform, the company added.

Lukassek/Shutterstock

The addition of AskBio will complement Bayers other cell and gene therapy company, BlueRock Therapeutics, which it acquired last year. BlueRock is developing induced pluripotent stem cells (iPSC), with its most advanced program aimed at Parkinsons disease.

Werner Baumann, chairman of the Board of Management at Bayer, said the acquisition of AskBio significantly advances the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science and contribute to the development of therapies that can prevent or cure diseases caused by genetic defects. Baumann said the goal is in line with the companys purpose of science for a better life.

As part of our strategy, we are building new therapeutic platforms including cell and gene therapies, Stefan Oelrich, president of the Bayers Pharmaceuticals Division said in a statement. As an emerging leader in the rapidly advancing field of gene therapies, the expertise and portfolio of AskBio supports us in establishing highly innovative treatment options for patients and further strengthens our portfolio. We want to help patients whose medical needs are not yet met by todays treatment options and we are looking forward to work together with the team at AskBio.

Read the original:
Bayer Acquires AskBio to Expand Gene Therapy Platform - PharmaLive

Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? – SurvivorNet

By Stem Cell Treatment

Dr. Jakub Svoboda Penn Medicine

If youve already gone through a round of treatment for diffuse large B-cell lymphoma and it didnt work, or your cancer came back after treatment, your doctor might start talking to you about having an autologous stem cell transplant. This therapy involves getting high doses of chemotherapy to get rid of your cancer cells, followed by an infusion of stem cells taken from your blood or bone marrow before treatment, to replenish your bodys supply of healthy blood cells.

Related: What is Autologous Stem Cell Transplant?

A stem cell transplant can be a pretty grueling treatment that involves getting very high doses of chemotherapy, spending three to four weeks in the hospital, and enduring side effects like nausea, vomiting, mouth pain, infections, bleeding, and lung inflammation. And after all of that, you still may not get the results you want.

If its going to cure the patient, I think its all worthwhile to go through, Dr. Jakub Svoboda, medical oncologist at Penn Medicine, tells SurvivorNet. If, on the other hand, a stem cell transplant isnt likely to result in a cure, it may not be a good choice for you.

One clue that can help your doctor decide whether a stem cell transplant is worth the risks involved is how well you responded to chemotherapy after your cancer relapsed. People with an aggressive lymphoma that didnt respond well to chemotherapy tend not to have a good outcome from a stem cell transplant.

Having a combination imaging test called a PET/CT scan before a stem cell transplant can help pinpoint your response to chemo, and let you avoid some potentially severe side effects if this treatment isnt likely to cure you. The PET/CT technology has allowed us to select the patients who will likely benefit from autologous STEM cell transplant, Dr. Svoboda says.

The PET/CT scan combines two common cancer imaging tests. PET stands for positron emission tomography. Before the test, you get an injection of a small amount of radioactive sugar, called fluorodeoxyglucose-18 (FGD-18). Because cancer cells use a lot more energy than healthy cells, they absorb the sugar in larger amounts. As the tracer collects in the cancer, it makes those areas light up and become visible, so your doctor can see them on the scan.

CT is short for computed tomography. It takes x-rays of your body from different angles, to create a cross-sectional view of your organs and tissues. The CT scan can reveal areas of your body that are enlarged from the cancer. It alone isnt sensitive enough to pick up metabolically active areas of cancer, which is why the two tests are combined.

A computer combines the PET and CT images to give your doctor a highly detailed, three-dimensional view of your cancer. Having both of these tests together can show your doctor not only whether your cancer is shrinking, but also if its still active.

When people still have some metabolic activity within shrinking areas of cancer, they actually dont do well with the transplant, Dr. Svoboda says.

Its very helpful for doctors to have the information from a PET/CT scan, Dr. Svoboda tells SurvivorNet. You can then offer that patient a different treatment or steer them toward some of the novel therapies.

One alternative to stem cell transplant is chimeric antigen receptor (CAR) T-cell therapy. Its a promising treatment for some people with aggressive non-Hodgkin lymphoma that hasnt responded to other treatments. CAR T-cell therapy involves genetically modifying your own immune cells so that they attack your cancer. CAR T-cell therapy or other treatments actually may have a better chance at working than transplanting in this setting, Dr. Svoboda says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jakub Svoboda is a medical oncologist at Penn Medicine, andassociate professor of medicine at the Hospital of the University of Pennsylvania. Read More

Dr. Jakub Svoboda Penn Medicine

Related: What is Autologous Stem Cell Transplant?

If its going to cure the patient, I think its all worthwhile to go through, Dr. Jakub Svoboda, medical oncologist at Penn Medicine, tells SurvivorNet. If, on the other hand, a stem cell transplant isnt likely to result in a cure, it may not be a good choice for you.

One clue that can help your doctor decide whether a stem cell transplant is worth the risks involved is how well you responded to chemotherapy after your cancer relapsed. People with an aggressive lymphoma that didnt respond well to chemotherapy tend not to have a good outcome from a stem cell transplant.

Having a combination imaging test called a PET/CT scan before a stem cell transplant can help pinpoint your response to chemo, and let you avoid some potentially severe side effects if this treatment isnt likely to cure you. The PET/CT technology has allowed us to select the patients who will likely benefit from autologous STEM cell transplant, Dr. Svoboda says.

The PET/CT scan combines two common cancer imaging tests. PET stands for positron emission tomography. Before the test, you get an injection of a small amount of radioactive sugar, called fluorodeoxyglucose-18 (FGD-18). Because cancer cells use a lot more energy than healthy cells, they absorb the sugar in larger amounts. As the tracer collects in the cancer, it makes those areas light up and become visible, so your doctor can see them on the scan.

CT is short for computed tomography. It takes x-rays of your body from different angles, to create a cross-sectional view of your organs and tissues. The CT scan can reveal areas of your body that are enlarged from the cancer. It alone isnt sensitive enough to pick up metabolically active areas of cancer, which is why the two tests are combined.

A computer combines the PET and CT images to give your doctor a highly detailed, three-dimensional view of your cancer. Having both of these tests together can show your doctor not only whether your cancer is shrinking, but also if its still active.

When people still have some metabolic activity within shrinking areas of cancer, they actually dont do well with the transplant, Dr. Svoboda says.

Its very helpful for doctors to have the information from a PET/CT scan, Dr. Svoboda tells SurvivorNet. You can then offer that patient a different treatment or steer them toward some of the novel therapies.

One alternative to stem cell transplant is chimeric antigen receptor (CAR) T-cell therapy. Its a promising treatment for some people with aggressive non-Hodgkin lymphoma that hasnt responded to other treatments. CAR T-cell therapy involves genetically modifying your own immune cells so that they attack your cancer. CAR T-cell therapy or other treatments actually may have a better chance at working than transplanting in this setting, Dr. Svoboda says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jakub Svoboda is a medical oncologist at Penn Medicine, andassociate professor of medicine at the Hospital of the University of Pennsylvania. Read More

Follow this link:
Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? - SurvivorNet

→←